Candace L Haddox

7PUBLICATIONS
53CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 06, 2026
Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.

|May 09, 2024
Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.

Gregory M Cote, Candace L Haddox, Edwin Choy

|Jan 18, 2024
Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.

Candace L Haddox, Michael J Nathenson, Emanuele Mazzola

|Aug 08, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.

Lars D Engstrom, Ruth Aranda, Laura Waters

Pageof 2

Frequent Collaborators

3 joint publications

Priscilla Merriam

3 joint publications

Andrew J Wagner

3 joint publications

Suzanne George

2 joint publications

Vinayak Venkataraman